Novogen Limited
140 Wicks Road
North Ryde,
NSW 2113
Australia - Map
Phone: 61 2 9878 0088
Fax: 61 2 9878 0055
Web Site: http://www.novogen.com
| Novogen Limited and its subsidiaries engage in the research and development of pharmaceutical products, and marketing of consumer healthcare products. The companys consumer healthcare products comprise Promensil, a range of natural products specifically for womens health; Vinalac, a probiotic formula to help prevent childhood allergies, such as eczema in children at risk of an allergy; Aliten for weight control; and Trinovin, for the enhancement and maintenance of mens health. It focuses on oncology, cardiovascular, dermatological, and anti-inflammatory programs. The companys programs include Phenoxodiol, a phase III investigational drug for late stage, chemoresistant ovarian cancer and prostate, and cervical cancers; Triphendiol, a phase I signal transduction inhibitor for the treatment of cholangiocarcinoma or bile duct cancer, and stage IIB through stage IV malignant melanoma; NV-128, a pre-clinical stage cancer compound to promote cancer cell death in multidrug resistant ovarian cancer cells by targeting the AKT-mTOR pathway; and GLYC-101, a phase II product for the treatment of wounds following laser ablation, burn wounds, surgical wounds, venous ulcers, and diabetic ulcers. Novogens programs also include NV-143, a derivative of triphendiol and a pan acting ant-cancer; NV-04, a program for cardiovascular disease; NV-27, an oral agent to prevent arterial restenosis following coronary artery angioplasty; and NV-07 for the protection of mice against UV-induced inflammatory changes in the skin and against UV-induced skin immune suppression. In addition, it develops NV-52 for the treatment of inflammatory bowel disease; and FAIMs, flavonoid anti-inflammatory molecules to avoid cardiovascular, gastrointestinal, and renal side effects associated with anti-inflammatory drugs. Novogen Limited offers its products in Australia, North America, and Europe. The company was founded in 1994 and is headquartered in North Ryde, Australia. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. David Ross Seaton B Bus KCAE, M Com UNSW, CPA, 55
Acting Chief Exec. Officer and Chief Financial Officer |
$
316.00K | N/A | Mr. Bryan Mark Palmer ,
Gen. Mang. of Operations |
$
155.00K | N/A | Dr. R. Koenig M.D., Ph.D., 49
Chief Exec. Officer of Glycotex Inc |
$
414.00K | N/A | Prof. Alan J. Husband Ph.D., DSc, FASM,
Research Director and Exec. Director |
$
233.00K | N/A | Mr. Ronald Lea Erratt FINA,
Company Sec. |
$
62.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.52% Nasdaq 0.00%
Profile
